stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Return on equity
Cytokinetics, Incorporated's return on equity over the twelve months to 30 September 2026 was 184.7%, down 12.8 percentage points from fiscal 2025 (197.5%). Over the past ten years it has ranged from −1,622.9% (fiscal 2019) to 226.0% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 197.5% | (28.53) |
| FY2024 | 226.0% | 13.04 |
| FY2023 | 213.0% | 785.11 |
| FY2022 | −572.2% | (451.61) |
| FY2021 | −120.5% | 127.96 |
| FY2020 | −248.5% | 1,374.38 |
| FY2019 | −1,622.9% | (1,466.31) |
| FY2018 | −156.6% | (31.41) |
| FY2017 | −125.2% | (145.35) |
| FY2016 | 20.2% | 66.88 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated | 184.7% |
| CORT Corcept Therapeutics Incorporated compare | 21.7% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −64.9% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement